

Sayens – Projet technologique

<https://www.sayens.fr/en/portefeuille-offres/projets-technologiques/fibrinhib/>

FIBRINHIB



European patent pending

Partner laboratory:
IMoPA UMR 7365 CNRS UL

Fibrosis treatment

Innovative immunotherapy

Context

Chronic or acute inflammation can lead to neosynthesis and massive accumulation of non-functional collagen affecting tissue function through a degenerative process called fibrosis.

Today, fibrosis is a major health problem because no treatment exists on the market. This project targets two pathologies:

- Idiopathic pulmonary fibrosis
- Hepatic fibrosis

This curative treatment aims to inhibit the synthesis of systemic collagen in order to eliminate the fibrotic process at the origin.

Innovation

The use of antibodies targeting the collagen precursor makes it possible to inhibit systemic collagen synthesis by acting directly on the source of the problem to stop the process.

This project is in line with the expectations of the market for innovative therapies by proposing the first curative treatment of fibrosis.

Benefits

- No treatment available
- Curative treatment of fibrosis
- Interest of big pharmaceutical companies
- Orphan drug status to facilitate development

Contact : ludmila.monteiro@sayens.fr